RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: CLINICOPATHOLOGICAL CHARACTERISTICS, MOLECULAR GENETIC ALTERATIONS. REVIEW.
... attention is now paid to the presence of driver mutations, such as telomerase reverse transcriptase promoter mutations TERT, BRAF V600E, NRAS, which show an aggressive genetic pattern; they can also be used for patient risk stratification when determining ... ....1530/ERC-15-0300. Epub 2015 Aug 25. PMID: 26307020. 74. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009 Dec;19(12):1381-91. doi: 10.1089/thy.2009.1611. PMID: 20001720. 75. Vasil'ev ...
Изменен: 28.04.2024Путь: Главная / Home / Publications
RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: CLINICOPATHOLOGICAL CHARACTERISTICS, MOLECULAR GENETIC ALTERATIONS. REVIEW.
2 2024
Изменен: 28.04.2024Путь: Главная / Публикации
Результаты поиска 1 2 из 2
Начало | Пред. | 1 | След. | Конец
Отсортировано по релевантности | Сортировать по дате